Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases |
Zhou, De
(Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University)
Xie, Wan-Zhuo (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Hu, Ke-Yue (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Huang, Wei-Jia (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Wei, Guo-Qing (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) He, Jing-Song (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Shi, Ji-Min (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Luo, Yi (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Li, Li (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Zhu, Jing-Jing (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Zhang, Jie (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Lin, Mao-Fang (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Ye, Xiu-Jin (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Cai, Zhen (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Huang, He (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) |
1 | Alizadeh AA, Eisen MB, Davis RE, et al (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-11. DOI ScienceOn |
2 | Bodoor K, Matalka I, Hayajneh R, Haddad Y, Gharaibeh W (2012). Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a Marker of Poor Prognosis. Asian Pac J Cancer Prev, 13, 3037-46. DOI ScienceOn |
3 | Chen Y, Zhang H, Xu A, et al (2006). Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer, 54, 95-102. DOI ScienceOn |
4 | Conconi A, Zucca E, Roggero E, et al (2000). Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol, 18, 61-73 DOI |
5 | Cunningham BA, Wang JL, Berggard I, Peterson PA (1973). The complete amino acid sequence of beta 2-microglobulin. Biochemistry, 12, 4811-22. DOI ScienceOn |
6 | Gross M, Top I, Laux I, et al (2007). Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res, 13, 1979-86. DOI ScienceOn |
7 | Gussow D, Rein R, Ginjaar I, et al (1987). The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol, 139, 3132-8. |
8 | Hassan U, Mushtaq A, Mamoon N, et al (2012). Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy. Asian Pac J Cancer Prev, 13, 1341-7. DOI ScienceOn |
9 | Hemmingsen L, Skaarup P (1977). Urinary excretion of ten plasma proteins in patients with renal carcinoma. Scand J Urol Nephro, 11, 41-6. DOI |
10 | Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK (2002). Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis, 23, 967-75. DOI ScienceOn |
11 | Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (2006). Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol, 24, 4301-8. DOI ScienceOn |
12 | Krol AD, le CS, Snijder S, et al (2003). Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol, 14, 131-9. DOI ScienceOn |
13 | Lenz G, Wright G, Dave SS, et al (2008). Stromal gene signatures in large-B-cell lymphomas. N Engl J Med, 359, 2313-23. DOI ScienceOn |
14 | Li X, Liu Z, Cao J, et al (2012). Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol, 91, 837-45. DOI |
15 | Naz E, Mirza T, Danish F (2011). Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry. Asian Pac J Cancer Prev, 12, 3335-9. |
16 | Pedersen LO, Hansen AS, Olsen AC, et al (1994). The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen. Scand J Immunol, 39, 64-72. DOI ScienceOn |
17 | Poulsen CB, Borup R, Nielsen FC, et al (2005). Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol, 74, 453-65. DOI ScienceOn |
18 | Rosenwald A, Wright G, Chan WC, et al (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, 1937-47. DOI ScienceOn |
19 | Shipp MA, Ross KN, Tamayo P, et al (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 8, 68-74. DOI ScienceOn |
20 | Shuster J, Gold P, Poulik MD (1976). Beta 2-microglogulin levels in cancerous and other disease states. Clin Chim Acta, 67, 307-13. DOI ScienceOn |
21 | Teasdale C, Mander AM, Fifield R, et al (1977). Serum beta2-microglobulin in controls and cancer patients. Clin Chim Acta, 78, 135-43. DOI ScienceOn |
22 | Townsend AR, Rothbard J, Gotch FM, et al (1986).The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 44, 959-68. DOI ScienceOn |
23 | Ward DG, Nyangoma S, Joy H, et al (2008). Proteomic profiling of urine for the detection of colon cancer. Proteome Sci, 6, 19. DOI ScienceOn |
24 | Yang J, Qian J, Wezeman M, et al (2006). Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10, 295-307. DOI ScienceOn |